Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267877 | 0.93 | PTGS2 (0.39) | PTGS2PTGS1TDP1MEN1KMT2A | |
| Nitroglycerin SCHEMBL11214377 | 0.90 | ALDH1A1 (0.47) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL4587225 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL4587241 | 0.86 | PTGS2 (0.45) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL16267973 | 0.86 | PTGS2 (0.49) | PTGS2PTGS1TDP1MEN1KMT2A | |
| SCHEMBL4369881 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15507452 | 0.84 | ALDH1A1 (0.37) | PTGS2PTGS1TDP1MEN1KMT2A | |
| Nitroglycerin SCHEMBL920644 | 0.82 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1 | |
| Nitroglycerin SCHEMBL15421 | 0.82 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL4367696 | 0.82 | PTGS2 (0.39) | PTGS2PTGS1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0769309-A2 | Extinguishing chain for fighting fires | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 1997-04-23 | — | — | EP | claimed |
| EP-3004293-A2 | ADDITIVE FOR CETANE NUMBER INCREASE OF DIESEL FUELS AND BIO-DIESEL FUELS AND ITS USE | Slovenská Technická Univerzita v Bratislave Strojnicka Fakulta (SK) | 2016-04-13 | — | — | EP | disclosed |
| EP-2614050-B1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm Biotech Srl (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| WO-2014193314-A2 | ADDITIVE FOR CETANE NUMBER INCREASE OF DIESEL FUELS AND BIO-DIESEL FUELS AND ITS USE | SLOVENSKÁ TECHNICKÁ UNIVERZITA V BRATISLAVE (SK) | 2014-12-04 | — | — | WO | disclosed |
| EP-2614050-A1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm S.p.A. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| WO-2012032479-A1 | L,5-DIARYL-2-ALKVLPVRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | ROTTAPHARM S.P.A. (IT) | 2012-03-15 | — | — | WO | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| EP-1711459-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-02 | — | — | EP | disclosed |
| EP-1711459-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070883-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
| EP-0769309-A2 | Extinguishing chain for fighting fires | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 1997-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885CA1 2474/4885 |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885PTGS1 2/4885CA1 2831/4885 |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | NOS3, PTGER3, PTGES3 | PTGS2 9/4885PTGS1 12/4885CA1 3642/4885 |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | PTGS2 21/4885PTGS1 16/4885CA1 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.